1 Sewell, H. F., Agius, R. M., Kendrick, D. & Stewart, M. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19. BMJ 370, m2722, doi:10.1136/bmj.m2722 (2020).
2 Lythgoe, M. P. & Middleton, P. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends in pharmacological sciences 41, 363-382, doi:10.1016/j.tips.2020.03.006 (2020).
3 Li, Q. et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 182, 1284-1294 e1289, doi:10.1016/j.cell.2020.07.012 (2020).
4 Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, doi:10.1016/j.cell.2021.03.055 (2021).
5 Tegally, H. et al. Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein. Nature, doi:10.1038/s41586-021-03402-9 (2021).
6 Ferrante, L. et al. Brazil's policies condemn Amazonia to a second wave of COVID-19. Nature medicine 26, 1315, doi:10.1038/s41591-020-1026-x (2020).
7 Murray, C. J. L. & Piot, P. The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection? Jama 325, 1249-1250, doi:10.1001/jama.2021.2828 (2021).
8 Abdool Karim, S. S. & de Oliveira, T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. The New England journal of medicine 384, 1866-1868, doi:10.1056/NEJMc2100362 (2021).
9 Zhao, M. M. et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal transduction and targeted therapy 6, 134, doi:10.1038/s41392-021-00558-8 (2021).
10 Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, doi:10.1016/j.cell.2020.02.052 (2020).
11 Zang, R. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Science immunology 5, doi:10.1126/sciimmunol.abc3582 (2020).
12 Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).
13 Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117, 11727-11734, doi:10.1073/pnas.2003138117 (2020).
14 Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263, doi:10.1126/science.abb2507 (2020).
15 Biniossek, M. L., Nagler, D. K., Becker-Pauly, C. & Schilling, O. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. Journal of proteome research 10, 5363-5373, doi:10.1021/pr200621z (2011).
16 Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nature reviews. Microbiology 19, 141-154, doi:10.1038/s41579-020-00459-7 (2021).
17 Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 102, 11876-11881, doi:10.1073/pnas.0505577102 (2005).
18 Wrobel, A. G. et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat Struct Mol Biol 27, 763-767, doi:10.1038/s41594-020-0468-7 (2020).
19 Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, doi:10.1038/s41586-020-2772-0 (2020).
20 Ke, Z. L. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498-+, doi:10.1038/s41586-020-2665-2 (2020).
21 Li, Q. et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell, doi:10.1016/j.cell.2021.02.042 (2021).
22 Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856-860, doi:10.1126/science.abd2985 (2020).
23 Papa, G. et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog 17, e1009246, doi:10.1371/journal.ppat.1009246 (2021).
24 Bussani, R. et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine 61, 103104, doi:10.1016/j.ebiom.2020.103104 (2020).
25 Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620, doi:10.1038/s41467-020-15562-9 (2020).
26 Sun, S. H. et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe 28, 124-133 e124, doi:10.1016/j.chom.2020.05.020 (2020).
27 Woo, J. T. et al. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. European journal of pharmacology 300, 131-135, doi:10.1016/0014-2999(95)00858-6 (1996).
28 Sasaki, M. et al. SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS pathogens 17, e1009233, doi:10.1371/journal.ppat.1009233 (2021).
29 Huang, X. et al. Amorphous nickel titanium alloy film: A new choice for cryo electron microscopy sample preparation. Prog Biophys Mol Biol 156, 3-13, doi:10.1016/j.pbiomolbio.2020.07.009 (2020).
30 Mastronarde, D. N. SerialEM: a program for automated tilt series acquisition on Tecnai microscopes using prediction of specimen position. Microscopy Microanalysis 9, 1182-1183 (2003).
31 Wu, C., Huang, X., Cheng, J., Zhu, D. & Zhang, X. High-quality, high-throughput cryo-electron microscopy data collection via beam tilt and astigmatism-free beam-image shift. Journal of structural biology, doi:10.1016/j.jsb.2019.09.013 (2019).
32 Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. Journal of Structural Biology 180, 519-530, doi:10.1016/j.jsb.2012.09.006 (2012).
33 Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. eLife 5, e18722 (2016).
34 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290-296, doi:10.1038/nmeth.4169 (2017).
35 Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature methods 14, 331 (2017).
36 Zhang, K. Gctf: Real-time CTF determination and correction. J Struct Biol 193, 1-12, doi:10.1016/j.jsb.2015.11.003 (2016).
37 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126-2132, doi:10.1107/S0907444904019158 (2004).
38 Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221, doi:10.1107/S0907444909052925 (2010).
39 Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.8 (2015).
40 Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605-1612, doi:10.1002/jcc.20084 (2004).
41 Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci, doi:10.1002/pro.3943 (2020).
42 Wu, S. et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nature communications 11, 4081, doi:10.1038/s41467-020-17972-1 (2020).
43 Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016-1020, doi:10.1126/science.abb7015 (2020).
44 Wang, J. et al. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein & cell 11, 776-782, doi:10.1007/s13238-020-00767-x (2020).
45 Tan, Y. Z. et al. Addressing preferred specimen orientation in single-particle cryo-EM through tilting. Nature Methods 14, 793-+, doi:10.1038/Nmeth.4347 (2017).